Clinical Trial Update: RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of RHB-204 for pulmonary Mycobacterium avium complex infection was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiectasis
• Pulmonary Mycobacterium Avium Complex Infection

Drugs mentioned

• RHB-204

Snippet

Sponsor: RedHill Biopharma Limited | Conditions: Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis | Phase 3 | Status: TERMINATED